ES2070134T3 - Inhibidores de lisil oxidasa. - Google Patents

Inhibidores de lisil oxidasa.

Info

Publication number
ES2070134T3
ES2070134T3 ES89103247T ES89103247T ES2070134T3 ES 2070134 T3 ES2070134 T3 ES 2070134T3 ES 89103247 T ES89103247 T ES 89103247T ES 89103247 T ES89103247 T ES 89103247T ES 2070134 T3 ES2070134 T3 ES 2070134T3
Authority
ES
Spain
Prior art keywords
oxidase inhibitors
lysil
lysil oxidase
inhibitors
lysylo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89103247T
Other languages
English (en)
Inventor
Michael G Palfreyman
Ian A Mcdonald
Philippe Bey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2070134T3 publication Critical patent/ES2070134T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

ESTA INVENCION RELATA LOS INHIBIDORES VERDADEROS DE OXIDASO LYSYLO Y SU UTILIZACION EN EL TRATAMIENTO DE ENFERMEDADES Y CONDICIONES ASOCIADAS CON LA DEPOSICION ANORMAL DE COLAGENO.
ES89103247T 1988-02-25 1989-02-24 Inhibidores de lisil oxidasa. Expired - Lifetime ES2070134T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16038288A 1988-02-25 1988-02-25
US16036488A 1988-02-25 1988-02-25

Publications (1)

Publication Number Publication Date
ES2070134T3 true ES2070134T3 (es) 1995-06-01

Family

ID=26856831

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89103247T Expired - Lifetime ES2070134T3 (es) 1988-02-25 1989-02-24 Inhibidores de lisil oxidasa.

Country Status (17)

Country Link
EP (1) EP0330218B1 (es)
JP (1) JP2772660B2 (es)
KR (1) KR890012641A (es)
CN (1) CN1035497A (es)
AT (1) ATE117549T1 (es)
AU (1) AU618076B2 (es)
CA (1) CA1338647C (es)
DE (1) DE68920757T2 (es)
DK (1) DK89489A (es)
ES (1) ES2070134T3 (es)
FI (1) FI890827A7 (es)
GR (1) GR3015470T3 (es)
IE (1) IE65553B1 (es)
IL (1) IL89388A (es)
NO (1) NO890801L (es)
NZ (1) NZ228068A (es)
PT (1) PT89839B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011504485A (ja) 2007-11-21 2011-02-10 ファーマクシス リミテッド Ｓｓａｏ／ｖａｐ−１のハロアリルアミン阻害剤およびその用途
BR112017019150B1 (pt) * 2015-03-06 2023-05-09 Pharmakea, Inc Compostos inibidores de lisil oxidase-like 2 fluorados, composição farmacêutica e uso desses compostos
GB201602934D0 (en) 2016-02-19 2016-04-06 Cancer Res Inst Royal Compounds
JP2020508996A (ja) * 2017-03-02 2020-03-26 ファーマクシス リミテッド リシルオキシダーゼのハロアリルアミンピラゾール誘導体阻害剤およびその使用
GB201809295D0 (en) 2018-06-06 2018-07-25 Institute Of Cancer Res Royal Cancer Hospital Lox inhibitors
GB201818750D0 (en) 2018-11-16 2019-01-02 Institute Of Cancer Res Royal Cancer Hospital Lox inhibitors
JP2025528475A (ja) * 2022-08-29 2025-08-28 シンタラ・リミテッド リシルオキシダーゼの新規選択的阻害剤
CN119732928A (zh) * 2024-12-26 2025-04-01 国家纳米科学中心 一种抑制胶原纤维形成的药物分子及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2891064A (en) * 1956-05-28 1959-06-16 Dow Chemical Co 3, 3-dichloro-2-methylallylamines
US4454158A (en) * 1981-06-01 1984-06-12 Merrell Toraude Et Compagnie Allyl amine MAO inhibitors
US4650907A (en) * 1985-12-05 1987-03-17 Merrell Dow Pharmaceuticals Inc. Nonaromatic fluoroallylamine MAO inhibitors
DD246990A1 (de) * 1986-02-26 1987-06-24 Univ Leipzig Verfahren zur herstellung von gamma-chlorallylverbindungen aus polychloralkanen

Also Published As

Publication number Publication date
DE68920757T2 (de) 1995-06-08
GR3015470T3 (en) 1995-06-30
ATE117549T1 (de) 1995-02-15
PT89839A (pt) 1989-10-04
EP0330218A3 (en) 1992-01-02
FI890827A0 (fi) 1989-02-21
KR890012641A (ko) 1989-09-18
IL89388A (en) 1995-03-15
AU618076B2 (en) 1991-12-12
DK89489A (da) 1989-08-26
AU3016089A (en) 1989-08-31
PT89839B (pt) 1994-04-29
IE65553B1 (en) 1995-11-01
EP0330218A2 (en) 1989-08-30
NZ228068A (en) 1991-11-26
NO890801L (no) 1989-08-28
JP2772660B2 (ja) 1998-07-02
DK89489D0 (da) 1989-02-24
EP0330218B1 (en) 1995-01-25
FI890827A7 (fi) 1989-08-26
IE890612L (en) 1989-08-25
JPH023626A (ja) 1990-01-09
CN1035497A (zh) 1989-09-13
DE68920757D1 (de) 1995-03-09
CA1338647C (en) 1996-10-15
NO890801D0 (no) 1989-02-24

Similar Documents

Publication Publication Date Title
EP0374440A3 (en) Inhibitors of lysyl oxidase
DE10199020I1 (de) Galanthamin oder dessen Analoge zur Behandlung der Alzheimerschen Krankheit
DE69231674D1 (de) Inhibitoren der dipeptidyl-aminopeptidase vom typ-iv
ES2106112T3 (es) Derivados de indano-2-mercaptoacetilamida con una actividad inhibidora de encefalinasa y de ace.
TR199801919T2 (xx) Rapamisin t�revlerinin damar hastal�klar� ve yabanc� doku naklinde kullan�m�.
ES2148229T3 (es) Eteres y tioeteres en la posicion 17 de 4-aza-esteroides.
ES2106965T3 (es) Nuevas 4-aza-5alfa-androstan-3-onas 7beta-sustituidas como inhibidores de 5alfa-reductasa.
ES2061621T3 (es) Nuevas lactamas triciclicas que contienen sulfhidrilo y sus metodos farmacologicos de uso.
ES2093819T3 (es) Procedimiento y composicion para determinar la susceptibilidad antimicrobiana de la mayoria de los organismos gram positivos clinicamente significativos.
ES2056180T3 (es) Nuevos derivados de 2'-halometiliden, 2'-eteniliden y 2'-etinil citidina.
DK0970130T3 (da) Glycosaminoglycaner med høj antithrombotisk aktivitet
ES2070134T3 (es) Inhibidores de lisil oxidasa.
ES2064119T3 (es) Nuevos derivados de aminobenzosultam como inhibidores de la lipoxigenasa.
ES2061447T3 (es) Compuestos con efecto nootropo, agentes que los contienen y su empleo en el tratamiento y la profilaxis de disfunciones cognitivas.
ES2078904T3 (es) Nuevos derivados de neplanocina.
ES2068714T3 (es) Derivados de pirimidina para aumentar la actividad antitumoral.
ES2157332T3 (es) Procedimiento que indica la neutralizacion de las soluciones que desinfectan las lentes de contacto.
ES2142490T3 (es) Ciclopeptolidos.
MX9304626A (es) Derivados heterociclicos utiles en el tratamiento de enfermedades cardiovasculares.
ES2058349T3 (es) Utilizacion de betabloqueadores para el tratamiento de la progresion de la miopia axial infantil.
ES2026485T3 (es) Esteres de salsalato con guayacol para tratar bronconeumopatias flogisticas.
ES2043596T3 (es) Feniloxazolonas cardiotonicas.
BR8700693A (pt) Expelentes de microbios fitopatogenicos e composicao expelente de microbios fitopatogenicos
ES2062332T3 (es) Benzoxazolonas antiinflamatorias.
ZA9610073B (en) Method of using beta-interferons to treat restenosis

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 330218

Country of ref document: ES